Optimizing the Delivery of Cancer Drugs That Block Angiogenesis

An optimized MNK1b aptamer, apMNKQ2, and its potential use as a

Systems biology of angiogenesis signaling: Computational models

Combination of anti-angiogenic therapy and immune checkpoint

Less Is More: Developments in Nanotechnology for Antirestenosis

Failure to launch commercially-approved mesenchymal stromal cell

Cancer combination therapies by angiogenesis inhibitors; a

Anti-angiogenic drug scheduling optimisation with application to

MORE